Loading…
Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms
Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and...
Saved in:
Published in: | Journal of pharmaceutical investigation 2015, 45(5), , pp.449-460 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3 |
container_end_page | 460 |
container_issue | 5 |
container_start_page | 449 |
container_title | Journal of pharmaceutical investigation |
container_volume | 45 |
creator | Chakma, Suharto Khadka, Prakash Jo, Kanghee Kim, Hyeongmin Ro, Jieun Park, Kyunghee Karki, Sandeep Barua, Sonia Lee, Jaehwi |
description | Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin
®
(Dibasic Calcium Phosphate Anhydrous), Pineflow
®
(Porous-structured Maltodextrin), Neusilin
®
(Magnesium Alumino metasilicate) and Aerosil
®
(Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography. |
doi_str_mv | 10.1007/s40005-015-0192-1 |
format | article |
fullrecord | <record><control><sourceid>nrf_cross</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_960778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_kci_go_kr_ARTI_960778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMoOHQ_wLtcelNN0iZtLsfwYzAQdF6HtDnZsnWJJC26f29rd-1FeAPneQ6cF6E7Sh4oIeVjKgghPCN0fJJl9ALNGJF5JhgtLs9_zjm7RvOU9mSkBa0qOUO7j9D2tWtdd8Lgd9o3cATf4WBxAy004cfVuE_Ob3EKrTPOOjB48w3gcUWwDRF3Oxjz2Le6c8GPaqfrFjpsQtLbaZhu0ZXVbYL5OW_Q5_PTZvmard9eVsvFOmtYLmhmLGMlpY2WIgfGGRe8YIbkxmomaimJkUUFxkIlGIcSpJVU2jLPNTBrS5PfoPtpr49WHRqngnZ_uQ3qENXifbNSUpCyrAaUTmgTQ0oRrPqK7qjjSVGixmLVVKwailVjsYoODpucNLB-C1HtQx_9cNE_0i893HuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><source>Springer Link</source><creator>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</creator><creatorcontrib>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</creatorcontrib><description>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin
®
(Dibasic Calcium Phosphate Anhydrous), Pineflow
®
(Porous-structured Maltodextrin), Neusilin
®
(Magnesium Alumino metasilicate) and Aerosil
®
(Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</description><identifier>ISSN: 2093-5552</identifier><identifier>EISSN: 2093-6214</identifier><identifier>DOI: 10.1007/s40005-015-0192-1</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Research Article ; 약학</subject><ispartof>Journal of Pharmaceutical Investigation, 2015, 45(5), , pp.449-460</ispartof><rights>The Korean Society of Pharmaceutical Sciences and Technology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</citedby><cites>FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002040841$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Chakma, Suharto</creatorcontrib><creatorcontrib>Khadka, Prakash</creatorcontrib><creatorcontrib>Jo, Kanghee</creatorcontrib><creatorcontrib>Kim, Hyeongmin</creatorcontrib><creatorcontrib>Ro, Jieun</creatorcontrib><creatorcontrib>Park, Kyunghee</creatorcontrib><creatorcontrib>Karki, Sandeep</creatorcontrib><creatorcontrib>Barua, Sonia</creatorcontrib><creatorcontrib>Lee, Jaehwi</creatorcontrib><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><title>Journal of pharmaceutical investigation</title><addtitle>Journal of Pharmaceutical Investigation</addtitle><description>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin
®
(Dibasic Calcium Phosphate Anhydrous), Pineflow
®
(Porous-structured Maltodextrin), Neusilin
®
(Magnesium Alumino metasilicate) and Aerosil
®
(Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Research Article</subject><subject>약학</subject><issn>2093-5552</issn><issn>2093-6214</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kF1LwzAUhoMoOHQ_wLtcelNN0iZtLsfwYzAQdF6HtDnZsnWJJC26f29rd-1FeAPneQ6cF6E7Sh4oIeVjKgghPCN0fJJl9ALNGJF5JhgtLs9_zjm7RvOU9mSkBa0qOUO7j9D2tWtdd8Lgd9o3cATf4WBxAy004cfVuE_Ob3EKrTPOOjB48w3gcUWwDRF3Oxjz2Le6c8GPaqfrFjpsQtLbaZhu0ZXVbYL5OW_Q5_PTZvmard9eVsvFOmtYLmhmLGMlpY2WIgfGGRe8YIbkxmomaimJkUUFxkIlGIcSpJVU2jLPNTBrS5PfoPtpr49WHRqngnZ_uQ3qENXifbNSUpCyrAaUTmgTQ0oRrPqK7qjjSVGixmLVVKwailVjsYoODpucNLB-C1HtQx_9cNE_0i893HuA</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Chakma, Suharto</creator><creator>Khadka, Prakash</creator><creator>Jo, Kanghee</creator><creator>Kim, Hyeongmin</creator><creator>Ro, Jieun</creator><creator>Park, Kyunghee</creator><creator>Karki, Sandeep</creator><creator>Barua, Sonia</creator><creator>Lee, Jaehwi</creator><general>Springer Netherlands</general><general>한국약제학회</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ACYCR</scope></search><sort><creationdate>201510</creationdate><title>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</title><author>Chakma, Suharto ; Khadka, Prakash ; Jo, Kanghee ; Kim, Hyeongmin ; Ro, Jieun ; Park, Kyunghee ; Karki, Sandeep ; Barua, Sonia ; Lee, Jaehwi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Research Article</topic><topic>약학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chakma, Suharto</creatorcontrib><creatorcontrib>Khadka, Prakash</creatorcontrib><creatorcontrib>Jo, Kanghee</creatorcontrib><creatorcontrib>Kim, Hyeongmin</creatorcontrib><creatorcontrib>Ro, Jieun</creatorcontrib><creatorcontrib>Park, Kyunghee</creatorcontrib><creatorcontrib>Karki, Sandeep</creatorcontrib><creatorcontrib>Barua, Sonia</creatorcontrib><creatorcontrib>Lee, Jaehwi</creatorcontrib><collection>CrossRef</collection><collection>Korean Citation Index</collection><jtitle>Journal of pharmaceutical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chakma, Suharto</au><au>Khadka, Prakash</au><au>Jo, Kanghee</au><au>Kim, Hyeongmin</au><au>Ro, Jieun</au><au>Park, Kyunghee</au><au>Karki, Sandeep</au><au>Barua, Sonia</au><au>Lee, Jaehwi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms</atitle><jtitle>Journal of pharmaceutical investigation</jtitle><stitle>Journal of Pharmaceutical Investigation</stitle><date>2015-10</date><risdate>2015</risdate><volume>45</volume><issue>5</issue><spage>449</spage><epage>460</epage><pages>449-460</pages><issn>2093-5552</issn><eissn>2093-6214</eissn><abstract>Celecoxib is a non-steroidal, anti-inflammatory drug used in the treatment of pain and inflammation associated with rheumatoid arthritis, and several other inflammatory disorders. It is a class II compound according to the Biopharmaceutics Classification System owing to its low water solubility and high membrane permeability. The objective of this study was to improve the solubility and dissolution rate of celecoxib using solid surfactant technology that might be useful in developing solid dosage forms. Solid surfactant was developed by mixing and grinding together a liquid surfactant (Tween 80) with various inorganic carriers like Fujicalin
®
(Dibasic Calcium Phosphate Anhydrous), Pineflow
®
(Porous-structured Maltodextrin), Neusilin
®
(Magnesium Alumino metasilicate) and Aerosil
®
(Colloidal Silicon dioxide) in a mortar and pestle in different ratios of liquid surfactant and the carrier to obtain solid surfactants. The celecoxib tablets prepared with solid surfactants were then evaluated for their solubility and dissolution properties. Among the fillers used, Fujicalin showed the highest solubilization capacity for celecoxib. The dissolution behaviors of various tablets prepared with solidified surfactants were compared to those of conventional celecoxib tablets in a simulated gastric fluid. Celecoxib tablets prepared using solidified surfactants showed improved dissolution behaviors when compared to the conventional counterparts. Fujicalin solidified Tween 80 was further analyzed by powder X-ray diffraction analysis, differential scanning calorimetry thermographs and reverse phase high performance liquid chromatography.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><doi>10.1007/s40005-015-0192-1</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2093-5552 |
ispartof | Journal of Pharmaceutical Investigation, 2015, 45(5), , pp.449-460 |
issn | 2093-5552 2093-6214 |
language | eng |
recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_960778 |
source | Springer Link |
subjects | Biomedical and Life Sciences Biomedicine Research Article 약학 |
title | Solubility enhancement of celecoxib using solidified Tween 80 for the formulation of tablet dosage forms |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A40%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nrf_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Solubility%20enhancement%20of%20celecoxib%20using%20solidified%20Tween%2080%20for%20the%20formulation%20of%20tablet%20dosage%20forms&rft.jtitle=Journal%20of%20pharmaceutical%20investigation&rft.au=Chakma,%20Suharto&rft.date=2015-10&rft.volume=45&rft.issue=5&rft.spage=449&rft.epage=460&rft.pages=449-460&rft.issn=2093-5552&rft.eissn=2093-6214&rft_id=info:doi/10.1007/s40005-015-0192-1&rft_dat=%3Cnrf_cross%3Eoai_kci_go_kr_ARTI_960778%3C/nrf_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2361-df22711ca963e25256542d03dfa26b990d948edfe8625e7e9f919f733ae2ff7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |